The conspicuous interindividual differences in metabolism and urinary excretion of testosterone and its metabolites make it challenging to reveal testosterone doping. The variation in testosterone glucuronide excretion is strongly associated with a deletion polymorphism in the uridine diphosphate-glucuronosyltranferase (UGT) 2B17 gene.
T estosterone and synthetic androgenic congeners, commonly known as anabolic androgenic steroids are misused to enhance muscle strength and performance (reviewed in Refs. 1 and 2). Two problems make the detection of testosterone doping an especially challenging analytical problem in drug testing, namely to differentiate between exogenous and endogenous testosterone, and the fact that there are large differences in metabolism and urinary excretion of testosterone metabolites. Today a urinary ratio between the glucuronides of testosterone and epitestosterone (T/E) is used as a screening method (3). Ratios above 4.0 are indicative of testosterone intake and the samples will be subject to further testing. The T/E ratio has a much higher inter than intraindividual variability (4 -6) , and future test programs will be based on individual monitoring rather than population-based reference values (7, 8) .
The overwhelming part of the interindividual variation in T/E ratios may be ascribed to genetic variability (9, 10) . We have demonstrated that a common deletion polymorphism in the gene coding for uridine diphosphate-glucuronosyltranferase (UGT) 2B17 (11) is strongly associated with testosterone glucuronide levels in urine (4) and that 40% of the individuals lacking the UGT2B17 gene would never reach the cutoff ratio of 4.0 used today after a single dose of 360 mg testosterone (6) . We have also shown that a thymine greater than cytosine (A1 Ͼ A2) promoter polymorphism in the CYP17 gene is associated with lower urinary epitestosterone excretion resulting in 64% higher T/E ratios in homozygotes, increasing the risk of falsepositive doping test results (12) .
Sottas et al. (reviewed in Ref. 13 ) have developed a statistical method for interpretation of doping tests based on empirical Bayesian inferential technique for longitudinal profiling (7, 8) . The test progressively switches the focus from comparison with a population-based reference value to comparison of individual related values. This method drastically reduces both false-positive and false-negative doping test results. Other biological information about the athlete added to the method (e.g. age, gender, ethnic origin, etc.) reduces the betweensubject variance (8) . In addition, we have recently demonstrated that introduction of information on UGT2B17 genotype to the method gives a substantial further improvement of the test (14) .
Individuals homozygous for the UGT2B17 deletion (del/del) have no or negligible amounts of urinary testosterone glucuronide (4), whereas the excretion of the two major testosterone metabolites, androsterone glucuronide, and etiocholanolone glucuronide is excreted at slightly lower or the same as in individuals with one (ins/ del) or two (ins/ins) alleles of the UGT2B17 gene (4). The UGT2B17 polymorphism is not associated with any variation in serum testosterone concentration (4) .
The metabolic inactivation of steroids by sulfation is important in the regulation of intracellular steroid activity (15, 16) . Human cytosolic sulfotransferases constitute the major phase II drug metabolism superfamily responsible for the sulfation of numerous exogenous and endogenous compounds (17, 18) . The major steroid precursor in humans is dehydroepiandrosterone, which is converted into both androgens and estrogens in peripheral tissues (15) . It exists in the circulation predominantly as the sulfated form (19) . Sulfation is not a major metabolic pathway for testosterone, but we hypothesized that the compromised glucuronidation capacity in UGT2B17 del/del individuals is compensated for by increased sulfation.
Because of the shortcomings of the T/E ratio as marker for testosterone doping, it is important to identify new biomarkers that could be used for detecting testosterone abuse. Sulfated steroids may serve as additional biomarkers for androgen abuse.
Gas chromatography coupled to mass spectrometry used for the determination of endogenous anabolic steroids (e.g. T/E ratio) in human urine is a common method for World Anti-Doping Agency-accredited laboratories, even though the number of liquid chromatographic-mass spectrometric methods for direct measurement of steroid conjugates has increased in the past years (20 -25) . We have developed a new ultraperformance liquid chromatographic tandem mass spectrometric method (UPLC-MS/ MS) for solid-phase extracted (SPE) human urine for simultaneous determination of 10 different sulfo-and glucuronide-conjugated steroids. The method is based on stable isotope dilution quantification.
The aim of our study was to identify additional biomarkers to reveal testosterone abuse and to elucidate alternative metabolic pathways for testosterone in UGT2B17 del/del individuals. For this purpose we used our new method to analyze urine samples from 54 healthy men, who received a single dose of testosterone enanthate.
Subjects and Methods

Subjects and design
Study subjects included 54 healthy male volunteers aged 18 -50 yr (mean 30.6 Ϯ 7.0 yr) with two (n ϭ 13), one (n ϭ 24), or no (n ϭ 17) allele (ins/ins, ins/del, or del/del) of the UGT2B17 gene. The study population has been described in more detail elsewhere (6) . All participants gave informed consent consistent with the approval of the Ethics Review Board. The participants were given 500 mg testosterone enanthate as a single im dose of Testoviron Depot (kindly provided by Schering Nordiska AB, Solna, Sweden) equivalent to 360 mg testosterone. Before administration (d 0) urine samples were collected for analyses. Urine was further collected on d 1-9, 11, 13, and 15. All samples were collected between 0700 and 1100 h. Adverse drug reactions were monitored from the time of screening until d 15 after administration of testosterone. No major adverse drug reactions were registered. No follow-up was needed. The study was conducted according to the Helsinki Declaration and the ICH Harmonised Tripartite Guideline for Good Clinical Practice. The UGT2B17 deletion polymorphism in these subjects had been genotyped by real-time PCR analysis in our previous study (6) . were purchased from NMI (Pymble, Australia). Methanol was bought from Lab-Scan (Poch Sa, Swinskiego, Poland) and ammonium acetate, ammonia and acetic acid from Merck KGaA (Darmstadt, Germany). Two urine blanks were collected from a prepubertal boy and prepubertal girl, which were used for calibrators and control samples, respectively. The urine blank samples were analyzed both by Gas chromatography coupled to mass spectrometry and UPLC-MS/MS before use to quantify any sublevels of the endogenous steroids listed above. Standard stock solutions containing steroid glucuronides and sulfates were prepared in methanol. Intermediate solutions, stored in Ϫ20 C, were prepared by serial dilutions of stock solutions to adequate concentrations. Calibrators (n ϭ 8) were freshly prepared at every batch analysis by diluting the intermediate solutions with urine blank (1:20 urine, from the prepubertal boy). Two quality control samples, low quality control sample (QCL) and a high-quality control sample (QCH), were prepared in urine blank (from the prepubertal girl) and stored in a freezer between batch analyses. Internal standard solution (ISTD) was prepared in water by diluting the deuterium-labeled conjugates listed above to relevant concentrations.
Materials
Sample preparation
Sample preparation, except for the centrifugation and evaporation step, was performed by a Xiril X-100 (Xiril AG, Hombrechtikon, Switzerland) pipetting robot. One milliliter sample and 20 l ISTD was added to a SPE Oasis HLB 96-well plate, 10 mg (Waters Associates, Milford, MA). The SPE plate was washed with 1 ml 0.1% acetic acid, 1 ml 0.1% ammonia, and 0.5 ml 10% MeOH and centrifuged subsequently. The analytes were eluted from the SPE plate into a 96-well plate with 2 ϫ 0.2 ml acetone. After evaporation, the residue was reconstituted with 200 l aqueous solution of 20% MeOH. The injection volume was 5 l.
Chromatographic separation
Waters Acquity ultraperformance liquid chromatographic (UPLC) system was used to perform the separation on Waters Acquity UPLC BEH RP18 column 50 ϫ 2.1 mm with 1.7-m particles. The mobile phases were 5 mM NH 4 Ac adjusted by ammonia to pH 9.6 (A) and MeOH (B). Separation was performed with a flow rate at 0.75 ml/min and a column temperature at 50 C by the following gradient; initial mobile phase composition was 30% B with a linear gradient to 35% B at 4.0 min followed by another increasing gradient to 90% B at 7.5 min, which was maintained to 8.0 min. The organic modifier was decreased to initial condition (30%) at 8.1 min and the final equilibration time was 9.0 min.
Mass spectrometric method
A Waters Micromass Quattro Premier triple-quadrupole instrument (Waters Associates, Manchester, UK) operating with fast polarity switching in multiple reaction mode (MRM) was used to detect the target analytes in the method. An electrospray probe was interfaced between the UPLC and the mass spectrometry system. The electric potential was set to 0.5 kV and the nitrogen desolvation gas flow and temperature was 1100 liters/h and 375 C, respectively. The ion source was heated to 120 C. Argon gas at a pressure of 3.5-4.5 ϫ 10 Ϫ3 mbar was used for product ion fragmentation in the T-wave collision cell. The method uses 20 msec dwell time for all MRM channels and 20 msec time between the polarity switching, giving at least 10 data points for all substances. Precursor (protonated, deprotonated, or ammonium adduct of the molecular ion) and product ions of each analyte were obtained by infusing 5-10 l/min of solutions of the reference substances (ϳ2 g/ml) to a tee connector between the outlet of the UPLC flow and the electrospray probe. The selected precursors, precursor ions, product ions, and collision offset are listed in Supplemental Table  1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org.
Batch analysis
One batch consisted of samples, calibrators, and blank and control samples, which were injected from the 96-well plate to the UPLC system. Urine blank and control samples, low and high, were analyzed every 13 samples. All samples were analyzed within 1 month, divided into 10 batches.
Data evaluation
Integration, calibration, and data evaluation was performed by the TargetLynx software (Waters Associates, Manchester, UK).
The between-subject variation in urine dilution was corrected for by dividing the concentration values by the urinary creatinine (cr) concentration, which was determined by colorimetric analysis (DRI Creatinine-Detct Test; Thermo Fisher Scientific, Waltham, MA). The areas under the curves (AUC) of the different urinary steroids were calculated using the trapezoidal rule. Statistical analyses were performed by one-way ANOVA, the Student's t test, or, when the data were not normally distributed, Kruskal Wallis ANOVA or the Mann-Whitney U test, if not specified otherwise.
Results
The UPLC-MS/MS method
The UPLC method was developed to analyze one batch within 24 h to avoid possible changes of the sample pending injection, e.g. evaporation, degradation, and/or adsorption to vial surface. The chromatographic separation is demonstrated in Fig. 1 , with three stacked integrated ion chromatograms, of 10 different analytes, from injections of a quality control sample (QCL) and two samples from the study (ins/ins and del/del) 5 d after the testosterone dose.
During method development dehydroepiandrosterone sulfate (DHEAS) was observed as a coeluting peak with EPS when detected in electrospray negative mode. To exclude the DHEAS as interference, detection of EPS was performed in positive mode and a longer gradient (20 min), lower flow rate (0.25 ml/min), and a longer column (10 cm) was used to baseline resolve DHEAS from EPS.
Ion suppression/enhancement setup according to Annesley (26) was investigated by postcolumn continuous infusion of compounds of interest with simultaneous injection of a solid-phase extracted urine sample. There were no indications of ion suppression in which the target analytes were eluted. In any case of matrix effect, the stable isotope internal standard will correct any suppression/enhancement for the corresponding analyte.
The recovery of the SPE method was investigated by two experiments: 1) extraction of one calibrator together with the ISTD and 2) extraction of a urine blank together with the ISTD into a test tube containing intermediate solution (corresponding to the concentrations in the calibrator used in experiment 1). The recovery ranged between 72.7% (DHTG) and 99.9% (ETS).
The sensitivity of the method for all substances, calculated by a signal-to-noise ratio of 3:1, was estimated from 0.03 ng/ml (EPS) to 1 ng/ml (AS). To achieve better method sensitivity, the reconstitution volume (200 l) may be reduced in the final sample preparation step.
The quality control data are presented in Supplemental Table 2 . The between-batch variances for the control samples were satisfactory and ranged from 4.17% (TS, high quality control sample) to 16.6% (EPS, QCL). The explanation of the high bias values of the QCL for ETG (ϩ59.6%), AG (ϩ63.2%) and AS (ϩ40.4%) may be due to the different steroid profile from the two different urine blanks (the concentration of the three steroid conjugates in the prepubertal girl blank were found to be approximately 120, 75, and 20 ng/ml, respectively, higher than the urine blank from the prepubertal boy). Supplemental Fig. 1 shows the graph of quality control samples of TG demonstrating the inter-and intraday variation during the complete batch analysis. The precision and accuracy of the method was Ϯ15% or less, indicating an acceptable level for bioanalytical quantitative methods.
Baseline urinary steroids
The individuals were divided into three groups according to UGT2B17 genotype: ins/ins, ins/del, and del/del. There was no difference in TS levels between the groups (P ϭ 0.3), whereas, as shown before, the del/del group had significantly lower baseline TG levels (Table 1) . Only a minor part of the urinary testosterone was sulfated except in the del/del individuals, in whom it accounted for 50% of the testosterone conjugates. In contrast, EPS corresponds to 25% on average (minimum 2% and maximum 60%) of the total urinary epitestosterone in all genetic The values are given as the mean with the 95% CI within parentheses. The P values were calculated using ANOVA or, when the data were not normally distributed, Kruskal Wallis ANOVA.
panels. The ETG levels tended to be lower in the del/del group (P ϭ 0.054), whereas the ETS levels were significantly higher in the del/del group (P ϭ 0.0031) compared with the other genotype panels ( Table 1 ). The glucuronidated and sulfated metabolites of DHT were not investigated in this study.
Urinary steroid profile after testosterone administration
To see whether TS could be used as a biomarker for testosterone abuse, the TS levels were measured before and on d 1-9, 11, and 13 and 15 d after an injection of 500 mg testosterone enanthate. The TS levels decreased to almost undetectable levels in less than a week for all three genotype groups without difference between the groups (Fig. 2) .
The rate of excretion increased for TG, AG, AS, ETG, and ETS (Fig. 3A) . As expected, the TG excretion increased much less in the del/del group compared with the ins/ins group. There was also a conspicuous decrease in urinary excretion of EPS and EPG after a testosterone dose (Fig. 3B) .
One metabolite, ETS, was always significantly higher in the del/del individuals compared with the other genotypes throughout the study period after the testosterone dose ( 
New biomarkers
A suitable biomarker that reveals testosterone abuse could be any ratio between metabolites that increases and decreases respectively after testosterone intake. AG and ETG levels had the highest increase among the metabolites measured; however, the interindividual differences were large. In four of the subjects (two del/del and two ins/del), the levels of ETG did not increase after the testosterone dose. The only metabolite that increased notably in all of our study subjects after a testosterone dose was AG. EPG decreases in all study subjects and is a suitable denominator of the ratio. During the study period of 15 d, the average increase in the AG to EPG ratio was 1470, 1040, and 1210 in the ins/ ins, ins/del, and del/del group, respectively. This is to be compared with an average increase in the TG to EPG ratio of 58 in the ins/ins group, 32 in the ins/del group, and 4.1 in the del/del group.
Discussion
We hypothesized that after a dose of testosterone enanthate, the TS levels would increase and serve as a good biomarker for doping with this steroid in individuals devoid of the glucuronidation enzyme, UGT2B17. However, the TS levels were markedly decreased to negligible levels about 5 d after the dose (Fig. 2) . Exogenous testosterone does not seem to be sulfated at all. Dehennin (27) showed that 95% of the TS originates from the testis and the decrease in testosterone sulfate levels may be the result of an endocrine feedback suppression of the secretion of LH (28, 29) with subsequent decrease in sulfation of endogenous testosterone. Testosterone is not a preferred substrate for liver sulfotransferase enzymes, with a 148-fold higher glucuronidation activity compared with sulfation activity for testosterone (30) . It is possible that an increase in urinary TS may be observed for oral formulations of testosterone, as indicated elsewhere (31), in which the concentrations in the liver are very high for the first hours after administration. However, TS will not serve as an appropriate biomarker for testosterone abuse.
Any ratio between an increasing and a decreasing testosterone metabolite has the potential to be used as a biomarker for testosterone abuse. The individual differences in the excretion of the sulfated metabolites were large. The maximum increase in the ETS excretion after a testosterone dose during 15 d was on average 31 Ϯ 32 nmol/mol cr and ranged between 1 and 130 nmol/mol cr with similar variation in all three genotypes. The variability in 
TABLE 2.
The ratio between AG and EPG in all subjects of the UGT2B17 ins/ins, ins/del, and del/del groups before (d 0), and 3, 7, and 15 d after an im injection of 500 mg testosterone enanthate, equivalent to 360 mg testosterone del/del subjects AG to EPG ratio median (range) ins/del subjects AG to EPG ratio median (range) the AS excretion was almost as large. Glucuronide conjugated androgens seem to be more appropriate biomarkers for testosterone abuse because the interindividual variation in excretion of glucuronide-conjugated metabolites is generally smaller, with the exception of testosterone glucuronide.
We propose that the AG to EPG ratio may serve as a complementary biomarker for testosterone abuse. AG levels increased after testosterone administration in all of our study subjects irrespective of the UGT2B17 genotype. The ratio was not significantly higher in the ins/ins and the ins/del group compared with the del/del group, neither before nor after the testosterone dose (Table 2) , which shows that this ratio is largely independent of the UGT2B17 polymorphism. However, the interindividual differences in these ratios were large. If shown to have use, it will be difficult to determine general cutoff ratios for this biomarker. Because of the marked increase of the ratio after the challenge with testosterone, the AG to EPG ratio has the potential to be used as a complement to the T/E ratio in the athlete's biological passport (13) , particularly in the del/del population in which the T/E ratio is an unsatisfactory marker of doping. Further studies in larger population samples are required to determine the usefulness of this biomarker approach.
Baseline urinary testosterone sulfate levels are low (22, 32) . One study suggested that individuals with low urinary TG also have low urinary TS (32) . In our study we observed a tendency of slightly higher TS levels in the del/del population compared with the other genotype groups, albeit not statistically significant (Table 1) . About 25% of the epitestosterone was sulfated, with no difference between the UGT2B17 genotypes. This is in accordance with previous studies (22, 32) .
Interestingly, the del/del group had significantly higher ETS levels than both the ins/del and the ins/ins group (Fig.  4) . This difference was maintained after a challenge with testosterone. Etiocholanolone is a 5␤-reduced metabolite of testosterone. This is the only metabolite we know of, so far, that is consistently higher in the del/del group. The higher levels may be a compensatory way for the del/del group to excrete androgens, even though this difference did not fully explain the difference between genotypes when all major metabolites of testosterone (androsterone and etiocholanolone glucuronide and sulfate) were accounted for.
There are a number of minor metabolites that were not measured in this study. Testosterone is also metabolized to estrogens catalyzed by CYP19, but no estrogens were included in the analytical work in this study. If these are considered, the difference between the ins/ins and the del/del individuals may be altered, but this remains to be studied.
In summary, the ratio between androsterone glucuronide and epitestosterone glucuronide may serve as a complement to the testosterone/epitestosterone glucuronide ratio in identification of subjects with intake of exogenous testosterone, preferentially in individuals devoid of the UGT2B17 enzyme (del/del genotype). Our studies also indicate that these individuals partly compensate for their compromised capacity to excrete testosterone by excreting higher levels of an alternative testosterone metabolite, etiocholanolone sulfate.
